Managing indolent lymphoma collaboratively Aug. 08, 2022 Overview Show transcript Overview Mayo Clinic Comprehensive Cancer Center hematologist and oncologist Jose (J.C.) C. Villasboas Bisneto, M.D., discusses follicular lymphoma and other indolent B-cell non-Hodgkin’s lymphomas. For many of these slow-growing diseases, cure is not the goal. Rather, a patient's care team must remain flexible and nimble in the treatment plan to manage the disease. Dr. Villasboas aims to take a collaborative approach with his patients' care teams at home to ensure long-term disease management with the most advanced therapies. Examples include immunotherapies such as CAR-T cell therapy, which is already approved by the FDA for patients with relapsed follicular lymphoma. Receive Mayo Clinic news in your inbox. Sign up Related ContentVideoCAR-T cell therapy: Current uses and future possibilities VID-20537203 Medical Professionals Managing indolent lymphoma collaboratively